Editor’s note: This is the final installment of a two-part series examining kratom and products containing its derivative, 7-OH. Part Two focuses on medical impacts and clinical concerns, while Part One examined regulatory and law enforcement responses. As regulators and law enforcement focus on the availability of 7-OH products, physicians say the compound’s increased potency is already influencing patient care and treatment decisions. During a recent Missouri Hospital Associationhosted session, medical professionals described the way products containing concentrated 7-OH differ from traditional kratom and why those differences matter in clinical settings, particularly when patients seek treatment for pain, dependence or withdrawalrelated symptoms. Dr. Doug Burgess provided a medical prospective on kratom and products containing concentrated 7-OH and the affect on patients in treatment settings. Burgess noted the growing availability of higher-potency products has changed how…